Immunogenicity and Safety of Different Doses of Fluzone® Influenza

NCT ID: NCT00253734

Last Updated: 2013-06-03

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE2
• Total Enrollment: 217 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2005-11-30
• Study Completion Date: 2006-11-30

Brief Summary

The purpose of this research study is to find out if giving the smaller dose of flu vaccine under the skin generates antibodies against flu compared to giving the vaccine the usual way, as a shot in the arm. If using smaller doses in this manner is effective, the current supply of vaccine could be used to make more doses to give to more people. About 217 healthy adults, 18 to 49 years of age, will participate. The study will be conducted at one site in the United States and subjects are expected to participate for about 6 months. Blood samples will be taken to assess the immune system response. Local and systemic safety will be evaluated in the 28 days following vaccination.

Detailed Description

This study is a randomized, prospective, active-controlled, single-center, open label, dose-ranging clinical trial of TIV (Fluzone®) administered to healthy 18-to-49 year old adults who did not receive 2003-2004, 2004-2005 and 2005-2006 influenza vaccine. Subjects will be randomized to one of 7 groups (4 intramuscular and 3 intradermal) to compare the immunogenicity and safety of different concentrations of the standard Fluzone® administered intradermally using the Mantoux technique to that of standard Fluzone® administered intramuscularly. The primary objective of the study is to compare the immunogenicity of injected Fluzone® across different dose levels and different routes of administration. The secondary objectives are to describe the number and proportions of subjects in each group experiencing any injection site or systemic symptoms and the proportion of subjects who experience moderate-to-severe symptoms post vaccination. Approximately 31 subjects per group (217 in total) will be enrolled with each group determined by dose and route of administration of vaccines. Subjects will be observed in the clinic for at least 30 minutes after immunization and will maintain a memory aid to record daily oral temperature and any systemic and local reactions for 7 days after the day of immunization. Subjects will be contacted by phone between 8 to 12 days after immunization to review their 7-day memory aid, including the assessment of their recorded daily oral temperature, any local or systemic reactions, and the occurrence of any other AEs and SAEs. Subjects will return at 28 (+/- 3) days after immunization to assess the occurrence of unsolicited AEs and SAEs and complete an acceptability and functional skill questionnaire. Serum for immunogenicity evaluations will be obtained prior to the first vaccination and approximately 28 (+/- 3) days post vaccination. The 2005-2006 formulation will be used for all seven groups.

Conditions

Influenza

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: PREVENTION
• Blinding Strategy: NONE

Study Groups

4

31 subjects to receive 15 mcg of TIV administered intramuscularly.

Group Type: ACTIVE_COMPARATOR

Fluzone® (IM)

Intervention Type: BIOLOGICAL

15, 9, 6, or 3 mcg of standard trivalent inactivated influenza vaccine (TIV) administered by the standard intramuscular route.

2

31 subjects to receive 6 mcg of TIV administered intradermally.

Group Type: EXPERIMENTAL

Fluzone®

Intervention Type: BIOLOGICAL

9, 6, or 3 mcg of standard trivalent inactivated influenza vaccine (TIV) administered by intradermal route (Mantoux technique).

1

31 subjects to receive 9 mcg of TIV administered intradermally.

Group Type: EXPERIMENTAL

Fluzone®

Intervention Type: BIOLOGICAL

9, 6, or 3 mcg of standard trivalent inactivated influenza vaccine (TIV) administered by intradermal route (Mantoux technique).

3

31 subjects to receive 3 mcg of TIV administered intradermally.

Group Type: EXPERIMENTAL

Fluzone®

Intervention Type: BIOLOGICAL

9, 6, or 3 mcg of standard trivalent inactivated influenza vaccine (TIV) administered by intradermal route (Mantoux technique).

5

31 subjects to receive 9 mcg of TIV administered intramuscularly.

Group Type: ACTIVE_COMPARATOR

Fluzone® (IM)

Intervention Type: BIOLOGICAL

15, 9, 6, or 3 mcg of standard trivalent inactivated influenza vaccine (TIV) administered by the standard intramuscular route.

7

31 subjects to receive 3 mcg of TIV administered intramuscularly.

Group Type: ACTIVE_COMPARATOR

Fluzone® (IM)

Intervention Type: BIOLOGICAL

15, 9, 6, or 3 mcg of standard trivalent inactivated influenza vaccine (TIV) administered by the standard intramuscular route.

6

31 subjects to receive 6 mcg of TIV administered intramuscularly.

Group Type: ACTIVE_COMPARATOR

Fluzone® (IM)

Intervention Type: BIOLOGICAL

15, 9, 6, or 3 mcg of standard trivalent inactivated influenza vaccine (TIV) administered by the standard intramuscular route.

Interventions

Fluzone® (IM)

15, 9, 6, or 3 mcg of standard trivalent inactivated influenza vaccine (TIV) administered by the standard intramuscular route.

Intervention Type: BIOLOGICAL

Fluzone®

9, 6, or 3 mcg of standard trivalent inactivated influenza vaccine (TIV) administered by intradermal route (Mantoux technique).

Intervention Type: BIOLOGICAL

Eligibility Criteria

Inclusion Criteria

• Subject is healthy, as determined by medical history and clinical assessment before entering the study.
• Between the ages of 18 and 49 (greater than or equal to 18 and less than 50)
• Provides written informed consent
• Able to attend all scheduled visits and to comply with all trial procedures
• For a woman, menopausal or surgically sterile or negative serum/urine pregnancy test within 24 hours prior to the time of vaccination.

Exclusion Criteria

• Breast-feeding or pregnant.
• History of receiving 2003-2004, 2004-2005 or 2005-2006 influenza vaccine.
• Known allergy to eggs or other components of the vaccine (e.g., thimerosal).
• History of a severe reaction following influenza vaccination, systemic hypersensitivity to any of the vaccine components, or history of a life-threatening reaction to a vaccine containing the same substances.
• History of Guillain-Barre Syndrome.
• Immunosuppression as a result of underlying illness or treatment.
• Use of oral steroids, parenteral steroids, or high-dose inhaled steroids (>800 mcg per day of beclomethasone dipropionate or equivalent) within 1 month prior to vaccination.
• Use of other immunosuppressive or cytotoxic drugs or radiation therapy within the six months prior to vaccination.
• Active neoplastic disease or history of any hematologic malignancy in the past 5 years (except localized skin or prostate cancer that is stable in the absence of therapy).
• Acute or chronic condition that (in the opinion of the Investigator) would render vaccination unsafe or would interfere with the evaluation of responses including, but not limited to the following: known chronic liver disease, significant renal disease, oxygen-dependent chronic lung disease, New York Heart Association Functional Class III or IV, unstable or progressive neurologic disorder, insulin-treated diabetes mellitus.
• Use of experimental vaccines or medications within the month prior to study entry, or expected use of experimental vaccines or medications during the entire study period after inoculation with study vaccine.
• Use of experimental devices or participation in a medical procedure trial within the month prior to study entry, or expected use of experimental devices or participation in a medical procedure trial during the entire study period.

13. Receipt of immunoglobulin or other blood product within 3 months prior to enrollment.

• Receipt of other licensed vaccines within the preceding 4 weeks or expected to receive a licensed vaccine within 28 days (prior to visit 2) following trial vaccination.
• Subject is enrolled in a conflicting clinical trial.
• Thrombocytopenia or bleeding disorder or therapy contraindicating IM vaccination.
• Female planning on becoming pregnant within one month of vaccination.
• Acute disease at the time of enrollment. (Acute disease is defined as the presence of a moderate or severe illness with or without fever).
• Febrile illness with temperature greater than or equal to 38 degrees Celsius (100.4 degrees Fahrenheit) within 72 hours prior to enrollment.
• Receipt of allergy shots within the preceding 7 days or expected to receive allergy shots within 7 days following vaccination.
• Any condition that, in the opinion of the investigator, would pose a health risk to the participant.
• Presence of any active skin disease at the injection site that, in the opinion of the Investigator, would impact vaccine delivery or assessment of vaccination site.
• History of drug abuse or alcohol abuse in the five years prior to enrollment.

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 49 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: Yes

Sponsors

National Institute of Allergy and Infectious Diseases (NIAID)

NIH

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Locations

Saint Louis University

St Louis, Missouri, United States

Countries

United States

Other Identifiers

05-0109

Identifier Type: -

Identifier Source: org_study_id